Equillium Inc (NAS:EQ)

$ 1.54 0 (0%) Market Cap: 54.29 Mil Enterprise Value: 22.73 Mil PE Ratio: 0 PB Ratio: 2.58 GF Score: 34/100

Equillium Inc Analyst & Investor Day Transcript
Oct 16, 2023
Equillium Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Equillium Inc at LD Micro Invitational Conference Transcript
Jun 07, 2023
Equillium Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) Transcript
Mar 30, 2023
Equillium Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Equillium Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Feb 02, 2023
Equillium Inc and Ono Pharmaceutical Co Ltd to Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab Call Transcript
Dec 06, 2022
Equillium Inc at Jefferies London Healthcare Conference Transcript
Nov 15, 2022
Equillium Inc at Stifel Healthcare Conference Transcript
Nov 15, 2022
Equillium Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Equillium Inc to Acquire Metacrine Inc - M&A Call Transcript
Sep 07, 2022
Equillium Inc to Discuss the Acquisition of Bioniz Therapeutics - M&A Call Transcript
Feb 16, 2022
Equillium Inc at JMP Securities Life Sciences Virtual Conference Transcript
Jun 16, 2021
Equillium Inc to Discuss EQUATE Study in aGVHD at EHA Virtual Congress Transcript
Jun 11, 2021
Equillium Inc at Jefferies Virtual London Healthcare Conference Transcript
Nov 19, 2020
Equillium Inc at Stifel Virtual Healthcare Conference Transcript
Nov 18, 2020
Equillium Inc at Rodman & Renshaw Global Investment Conference Sponsored by H C Wainwright Transcript
Sep 15, 2020
Equillium Inc to participate in BTIG's Virtual Biotechnology Conference Transcript
Aug 11, 2020
Equillium Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2020
Equillium Inc at RBC Global Healthcare Conference (Virtual) Transcript
May 20, 2020
Equillium Inc at Leerink Global Healthcare Conference Transcript
Feb 26, 2020
Equillium Inc at Jefferies London Healthcare Conference Transcript
Nov 21, 2019
Equillium Inc at Stifel Healthcare Conference Transcript
Nov 19, 2019
Equillium Inc Business Update - Conference Call Transcript
Oct 01, 2019
Equillium Inc at H C Wainwright Global Life Sciences Conference Transcript
Apr 08, 2019
Equillium Inc at Leerink Partners Global Healthcare Conference Transcript
Feb 28, 2019
Equillium Inc Guidance Call Transcript
Feb 26, 2019

Equillium Inc Guidance Call Transcript

Feb 26, 2019 / 09:30PM GMT

Release Date Price: $7.38 (+11.65%)

Transcript 8-K

Operator

Good afternoon and welcome to Equillium's Business Strategy Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. If you have any objections, you may disconnect at this time.

I would like to turn the call over to Christine Zedelmayer, Vice President of Operations at Equillium. Please go ahead.

Christine Zedelmayer

Equillium, Inc. - VP, Operations

Thank you, Jimmy, and thank you everyone for joining us this afternoon for Equillium's Business Update Conference Call. If you've not seen today's press release and our updated corporate presentation, please visit Equillium's website at www.equilliumbio.com.

Before turning the call over to Dan Bradbury, Equillium's Chairman and Chief Executive Officer, I would like to remind you that today's discussion will continue forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in today's press release, our corporate presentation and in our

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.